OncologyCE
LECTURECME

Updates in Hepatocellular Carcinoma: Clinical Decision-making Among an Array of New Options

Author(s)/Faculty: Ghassan K. Abou-Alfa, MD, MBA
Release Date: 5/24/2019Expiration Date: 5/23/2020
Credit Type: CMENumber of Credits: 0.75
Content Type: LectureProvider:
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the second leading cause of cancer-related deaths. Early detection and timely therapeutic intervention have significantly improved the 5-year survival rates for these patients, but until recently, few effective therapies were available. Recent approvals of therapeutic agents by the US Food and Drug Administration have supplemented the therapeutic armamentarium for the treatment of patients with HCC, with other emerging agents still being investigated in ongoing clinical studies. Within this recorded CME symposium, experts in the field discuss the latest advances in targeted therapies and checkpoint inhibitors for the management of patients with HCC. In addition, presentation of clinical cases provides guidance for the incorporation of recently approved therapies into treatment protocols.